Migraine - Epidemiology Forecast

List of Tables

Migraine Insights and Trends

According to DelveInsight's analysis, the total prevalent cases of migraine were ~ 92 million in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
Migraine is a highly prevalent, disabling neurological disorder characterized by recurrent attacks of moderate-to-severe headache, often accompanied by nausea, vomiting, photophobia, phonophobia, and other neurological symptoms.
Migraine diagnosis is standardized through ICHD-3 clinical criteria, but remains largely dependent on symptom history rather than an objective biomarker. This creates challenges in atypical or first-time presentations and in distinguishing migraine, particularly aura, from neurological mimics such as transient ischemic attack, creating a need for more objective diagnostic tools.
The migraine population is divided into acute/episodic and chronic migraine based on the number of headache days experienced per month. Acute or episodic migraine constitutes the vast majority of cases, accounting for approximately 95% of the migraine population, whereas chronic migraine affects only a small proportion of patients but is associated with a more severe and disabling disease burden. Within the acute/episodic migraine population, migraine without aura is the predominant subtype, representing approximately 85% of cases, while migraine with aura accounts for the remaining 15%.
Analysis suggests that low/mild-disability (Grades I-II) remain largely untreated, while treatment innovation is increasingly focused on the moderate-to-severe migraine population. Acute migraine patients are mostly concentrated in MIDAS little-to-mild disability, a segment largely ineligible for preventive treatment, while chronic migraine skews toward Grade IV.
Despite the high prevalence and substantial burden of migraine, treatment and prevention uptake remains relatively low across the 7MM. This is mainly due to underdiagnosis, limited healthcare-seeking behavior, delayed treatment initiation, inadequate access to specialists and appropriate therapies, affordability or reimbursement barriers, and poor treatment continuation or adherence.

Migraine Epidemiology Forecast in 7MM

2025 Prevalent Cases of Migraine: ~ 92 million
2036 Projected Prevalent Cases of Migraine: ~ 109 million
Migraine Growth Rate (2026-2036): 1.6% CAGR

DelveInsight's 'Migraine- Epidemiology Forecast - 2036' report delivers an in-depth understanding of the migraine, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Migraine Understanding and Diagnosis Algorithm

Migraine is a common, disabling neurological disorder characterized by recurrent attacks of moderate-to-severe headache, often accompanied by symptoms such as nausea, vomiting, and sensitivity to light and sound. Migraine can occur with or without aura, with migraine without aura being the more common presentation. Attacks typically last several hours to a few days and can substantially affect daily activities, work productivity, and quality of life. Diagnosis is primarily clinical and is based on the patient's medical history, symptom pattern, headache characteristics, and neurological examination. There is no single laboratory test or imaging procedure that confirms migraine. Clinicians generally assess the frequency, duration, location, and intensity of headaches, associated symptoms, presence of aura, and potential triggers while ruling out other causes of headache. Neuroimaging or additional investigations may be considered when patients present with atypical symptoms, abnormal neurological findings, or warning signs suggestive of a secondary headache disorder.

Migraine Epidemiology

Key Findings from Migraine Epidemiological Analysis and Forecast

The migraine epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Migraine Prevalent Cases, Migraine Prevalent Cases by Gender, Acute and Chronic Migraine Prevalent Cases, Menstrual Migraine Prevalent Cases, Migraine Prevalent Cases by Severity (MIDAS Grading), Chronic/Episodic Migraine Receiving Treatments, Chronic/Episodic Migraine Receiving Preventive Treatments covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2022 to 2036.

Migraine represents a substantial epidemiological burden across the 7MM, with adults accounting for the majority of prevalent cases, with 85 million cases in 2025, compared with the pediatric population with 7 million cases.
Migraine prevalence in Japan is relatively low compared with the overall 7MM burden. In 2025, Japan accounted for approximately 10.1% of the total migraine prevalent cases across the 7MM.
Migraine prevalence is consistently higher among women than men. This female predominance is largely associated with hormonal and biological factors, particularly fluctuations in estrogen during the menstrual cycle, which can increase susceptibility to migraine attacks. Menstrual-related migraine consequently represents a substantial component of the migraine burden among women, with approximately 30-70% of female migraineurs reporting attacks during the perimenstrual period.
In the United States, the acute migraine severity distribution in 2025 was estimated at 16 million, 7 million, 8 million, and 14 million for MIDAS Grade I, Grade II, Grade III, and Grade IV, respectively.
Despite the high prevalence of migraine in the United States, treatment uptake remains relatively low, with only around half of patients seeking or receiving treatment. Among EU4 and the UK countries, Italy reported the highest acute treatment pool, whereas France had the lowest; among EU4 and the UK countries, Germany reported the highest chronic treatment pool, whereas Spain had the lowest.

Scope of the Report:

The report covers a segment of an executive summary, a descriptive overview of migraine, explaining its causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Migraine patient population forecast

Report Key Strengths

Epidemiology-based (epi-based) bottom-up forecasting
11-year forecast
Patient burden trends (by geography)

FAQs:

What are the disease risks, burdens, and unmet needs of migraine? What will be the growth opportunities across the 7MM concerning the patient population with migraine?
What is the historical and forecasted migraine patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders' perspectives on the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Product Code: DIEI0320

1. Key Insights

2. Report Introduction

3. Executive Summary of Migraine

4. Epidemiology Forecast Methodology

5. Disease Background and Overview

5.1. Introduction
5.2. Signs and Symptoms
5.3. Risk Factors
5.4. Causes
- 5.4.1. Pathophysiology
- 5.4.2. Types
- 5.4.3. Diagnosis
- 5.4.4. Diagnostic Guidelines
  - 5.4.4.1. International Classification of Headache Disorders (ICHD-3) (2018)
  - 5.4.4.2. NICE Guidelines (2025)

6. Epidemiology and Patient Population of 7MM

6.1. Key Findings
6.2. Assumptions and Rationale
6.3. Migraine Prevalent Cases in the 7MM
6.4. The United States
- 6.4.1. Migraine Prevalent Cases in the United States
- 6.4.2. Migraine Prevalent Cases by Gender in the United States
- 6.4.3. Acute and Chronic Migraine Prevalent Cases in the United States
- 6.4.4. Menstrual Migraine Prevalent Cases in the United States
- 6.4.5. Migraine Prevalent Cases by Severity (MIDAS Grading) in the United States
  - 6.4.5.1. Acute Migraine Prevalent Cases by Severity in the United States
  - 6.4.5.2. Chronic Migraine Prevalent Cases by Severity in the United States
- 6.4.6. Chronic/Episodic Migraine Receiving Treatments in the United States
- 6.4.7. Chronic/Episodic Migraine Receiving Preventive Treatments in the United States
6.5. EU4 and the UK
- 6.5.1. Migraine Prevalent Cases in EU4 and the UK
- 6.5.2. Migraine Prevalent Cases by Gender in EU4 and the UK
- 6.5.3. Acute and Chronic Migraine Prevalent Cases in EU4 and the UK
- 6.5.4. Menstrual Migraine Prevalent Cases in EU4 and the UK
- 6.5.5. Migraine Prevalent Cases by Severity (MIDAS Grading) in EU4 and the UK
  - 6.5.5.1. Acute Migraine Prevalent Cases by Severity in EU4 and the UK
  - 6.5.5.2. Chronic Migraine Prevalent Cases by Severity in EU4 and the UK
- 6.5.6. Chronic/Episodic Migraine Receiving Treatments in EU4 and the UK
- 6.5.7. Chronic/Episodic Migraine Receiving Preventive Treatments in EU4 and the UK
6.6. Japan
- 6.6.1. Migraine Prevalent Cases in Japan
- 6.6.2. Migraine Prevalent Cases by Gender in Japan
- 6.6.3. Acute and Chronic Migraine Prevalent Cases by Type in Japan
- 6.6.4. Menstrual Migraine Prevalent Cases in Japan
- 6.6.5. Migraine Prevalent Cases by Severity (MIDAS Grading) in Japan
  - 6.6.5.1. Acute Migraine Prevalent Cases by Severity in Japan
  - 6.6.5.2. Chronic Migraine Prevalent Cases by Severity in Japan
- 6.6.6. Chronic/Episodic Migraine Receiving Treatments in Japan
- 6.6.7. Chronic/Episodic Migraine Receiving Preventive Treatments in Japan

7. Appendix

7.1. Bibliography
7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

Product Code: DIEI0320

List of Tables

Table 1: Summary of Migraine Epidemiology and Market (2025-2036)
Table 2: ICHD-3 Diagnostic Criteria
Table 3: ICHD-3 Diagnostic Criteria for Rare Migraine Types
Table 4: Tension-type headache, migraine (with or without aura) and cluster headache
Table 5: Prevention of Episodic Migraine Headache
Table 6: Total Prevalent Cases of Migraine in the 7MM in thousands (2022-2036)
Table 7: Migraine Prevalent cases in the United States in thousands (2022-2036)
Table 8: Migraine Prevalent Cases by Gender in the United States in thousands (2022-2036)
Table 9: Acute and Chronic Migraine Prevalent Cases in the United States in thousands (2022-2036)
Table 10: Menstrual Migraine Prevalent Cases in the United States in thousands (2022-2036)
Table 11: Acute Migraine Prevalent Cases by Severity in the United States in thousands (2022-2036)
Table 12: Chronic Migraine Prevalent Cases by Severity in the United States in thousands (2022-2036)
Table 13: Chronic/Episodic Migraine Receiving Treatments in the United States in thousands (2022-2036)
Table 14: Chronic/Episodic Migraine Receiving Preventive Treatments in the United States in thousands (2022-2036)
Table 15: Migraine Prevalent cases in Germany in thousands (2022-2036)
Table 16: Migraine Prevalent cases in France in thousands (2022-2036)
Table 17: Migraine Prevalent cases in Italy in thousands (2022-2036)
Table 18: Migraine Prevalent cases in Spain in thousands (2022-2036)
Table 19: Migraine Prevalent cases in the UK in thousands (2022-2036)
Table 20: Migraine Prevalent cases in EU4 and the UK in thousands (2022-2036)
Table 21: Migraine Prevalent Cases by Gender in Germany in thousands (2022-2036)
Table 22: Migraine Prevalent Cases by Gender in France in thousands (2022-2036)
Table 23: Migraine Prevalent Cases by Gender in Italy in thousands (2022-2036)
Table 24: Migraine Prevalent Cases by Gender in Spain in thousands (2022-2036)
Table 25: Migraine Prevalent Cases by Gender in the UK (2022-2036)
Table 26: Migraine Prevalent Cases by Gender in EU4 and the UK in thousands (2022-2036)
Table 27: Acute and Chronic Migraine Prevalent Cases in Germany in thousands (2022-2036)
Table 28: Acute and Chronic Migraine Prevalent Cases in France in thousands (2022-2036)
Table 29: Acute and Chronic Migraine Prevalent Cases in Italy in thousands (2022-2036)
Table 30: Acute and Chronic Migraine Prevalent Cases in Spain in thousands (2022-2036)
Table 31: Acute and Chronic Migraine Prevalent Cases in the UK in thousands (2022-2036)
Table 32: Acute and Chronic Migraine Prevalent Cases in EU4 and the UK in thousands (2022-2036)
Table 33: Menstrual Migraine Prevalent Cases in EU4 and the UK in thousands (2022-2036)
Table 34: Acute Migraine Prevalent Cases by Severity in Germany in thousands (2022-2036)
Table 35: Acute Migraine Prevalent Cases by Severity in France in thousands (2022-2036)
Table 36: Acute Migraine Prevalent Cases by Severity in Italy in thousands (2022-2036)
Table 37: Acute Migraine Prevalent Cases by Severity in Spain in thousands (2022-2036)
Table 38: Acute Migraine Prevalent Cases by Severity in the UK in thousands (2022-2036)
Table 39: Acute Migraine Prevalent Cases by Severity in EU4 and the UK in thousands (2022-2036)
Table 40: Chronic Migraine Prevalent Cases by Severity in Germany in thousands (2022-2036)
Table 41: Chronic Migraine Prevalent Cases by Severity in France in thousands (2022-2036)
Table 42: Chronic Migraine Prevalent Cases by Severity in Italy in thousands (2022-2036)
Table 43: Chronic Migraine Prevalent Cases by Severity in Spain in thousands (2022-2036)
Table 44: Chronic Migraine Prevalent Cases by Severity in the UK in thousands (2022-2036)
Table 45: Chronic Migraine Prevalent Cases by Severity in EU4 and the UK in thousands (2022-2036)
Table 46: Chronic/Episodic Migraine Receiving Treatments in Germany in thousands (2022-2036)
Table 47: Chronic/Episodic Migraine Receiving Treatments in France in thousands (2022-2036)
Table 48: Chronic/Episodic Migraine Receiving Treatments in Italy in thousands (2022-2036)
Table 49: Chronic/Episodic Migraine Receiving Treatments in Spain in thousands (2022-2036)
Table 50: Chronic/Episodic Migraine Receiving Treatments in the UK in thousands (2022-2036)
Table 51: Chronic/Episodic Migraine Receiving Treatments in EU4 and the UK in thousands (2022-2036)
Table 52: Chronic/Episodic Migraine Receiving Preventive Treatments in Germany in thousands (2022-2036)
Table 53: Chronic/Episodic Migraine Receiving Preventive Treatments in France in thousands (2022-2036)
Table 54: Chronic/Episodic Migraine Receiving Preventive Treatments in Italy in thousands (2022-2036)
Table 55: Chronic/Episodic Migraine Receiving Preventive Treatments in Spain in thousands (2022-2036)
Table 56: Chronic/Episodic Migraine Receiving Preventive Treatments in the UK in thousands (2022-2036)
Table 57: Chronic/Episodic Migraine Receiving Preventive Treatments in EU4 and the UK in thousands (2022-2036)
Table 58: Migraine Prevalent cases in Japan in thousands (2022-2036)
Table 59: Migraine Prevalent Cases by Gender in Japan in thousands (2022-2036)
Table 60: Acute and Chronic Migraine Prevalent Cases in Japan in thousands (2022-2036)
Table 61: Menstrual Migraine Prevalent Cases in Japan in thousands (2022-2036)
Table 62: Acute Migraine Prevalent Cases by Severity in Japan in thousands (2022-2036)
Table 63: Chronic Migraine Prevalent Cases by Severity in Japan in thousands (2022-2036)
Table 64: Chronic/Episodic Migraine Receiving Treatments in Japan in thousands (2022-2036)
Table 65: Chronic/Episodic Migraine Receiving Preventive Treatments in Japan in thousands (2022-2036)

List of Figures

Figure 1: Risks Factors
Figure 2: Pathophysiology
Figure 3: Total Prevalent Cases of Migraine in the 7MM in thousands (2022-2036)
Figure 4: Migraine Prevalent cases in the United States in thousands (2022-2036)
Figure 5: Migraine Prevalent Cases by Gender in the United States in thousands (2022-2036)
Figure 6: Acute and Chronic Migraine Prevalent Cases in the United States in thousands (2022-2036)
Figure 7: Menstrual Migraine Prevalent Cases in the United States in thousands (2022-2036)
Figure 8: Acute Migraine Prevalent Cases by Severity in the United States in thousands (2022-2036)
Figure 9: Chronic Migraine Prevalent Cases by Severity in the United States in thousands (2022-2036)
Figure 10: Chronic/Episodic Migraine Receiving Treatments in the United States in thousands (2022-2036)
Figure 11: Chronic/Episodic Migraine Receiving Preventive Treatments in the United States in thousands (2022-2036)
Figure 12: Migraine Prevalent cases in EU4 and the UK in thousands (2022-2036)
Figure 13: Migraine Prevalent Cases by Gender in EU4 and the UK in thousands (2022-2036)
Figure 14: Acute and Chronic Migraine Prevalent Cases in EU4 and the UK in thousands (2022-2036)
Figure 15: Menstrual Migraine Prevalent Cases in EU4 and the UK in thousands (2022-2036)
Figure 16: Acute Migraine Prevalent Cases by Severity in EU4 and the UK in thousands (2022-2036)
Figure 17: Chronic Migraine Prevalent Cases by Severity in EU4 and the UK in thousands (2022-2036)
Figure 18: Chronic/Episodic Migraine Receiving Treatments in EU4 and the UK in thousands (2022-2036)
Figure 19: Chronic/Episodic Migraine Receiving Preventive Treatments in EU4 and the UK in thousands (2022-2036)
Figure 20: Migraine Prevalent cases in Japan in thousands (2022-2036)
Figure 21: Migraine Prevalent Cases by Gender in Japan in thousands (2022-2036)
Figure 22: Acute and Chronic Migraine Prevalent Cases in Japan in thousands (2022-2036)
Figure 23: Menstrual Migraine Prevalent Cases in Japan in thousands (2022-2036)
Figure 24: Acute Migraine Prevalent Cases by Severity in Japan in thousands (2022-2036)
Figure 25: Chronic Migraine Prevalent Cases by Severity in Japan in thousands (2022-2036)
Figure 26: Chronic/Episodic Migraine Receiving Treatments in Japan in thousands (2022-2036)
Figure 27: Chronic/Episodic Migraine Receiving Preventive Treatments in Japan in thousands (2022-2036)

Migraine - Epidemiology Forecast - 2036

Description

Table of Contents

List of Tables

Migraine Insights and Trends

Migraine Epidemiology

Scope of the Report:

Report Insights

Report Key Strengths

FAQs:

Reasons to Buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Migraine

4. Epidemiology Forecast Methodology

5. Disease Background and Overview

6. Epidemiology and Patient Population of 7MM

7. Appendix

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Tables

List of Figures